Adimab can work with almost any format.
Adimab discovers better molecules by optimizing in the final therapeutic format.

At Adimab, we take a “biology first” approach to bispecific antibodies. There are over 80 different bispecific formats in the literature, each representing different arrangements of binding domains such as Fabs or scFvs and each with the potential to serve fundamentally different biological purposes. We offer a variety of bispecific formats that cover a wide range of biological functionality. During the initial work plan discussion, we focus on the therapeutic rationale, whether it be T-cell recruitment, ligand depletion, or some other biological function. These discussions ultimately lead to the selection of one or several preferred bispecific formats for the project. Today, over a third of Adimab’s projects involve bispecific formats. Adimab’s first bispecific molecule is currently in development and projected to enter the clinic in 2015.

Our key advantages are:

  • Ability to present full-length bispecifics on the surface of yeast
  • Dramatically improved success with expression in mammalian hosts
  • Creation of library diversities that are unprecedented for bispecific IgGs (>108)
  • Flexibility in choice of format:
    • Adimab proprietary constructs
    • Partner’s construct(s)
  • Selection for both targets simultaneously on criteria including:
    • Specificity
    • Cross-reactivity
    • Stability
    • Expressibility

Partners in Bispecifics: